"Factor Xa" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Activated form of factor X that participates in both the intrinsic and extrinsic pathways of blood coagulation. It catalyzes the conversion of prothrombin to thrombin in conjunction with other cofactors.
| Descriptor ID |
D015951
|
| MeSH Number(s) |
D08.811.277.656.300.760.315 D08.811.277.656.959.350.315 D12.776.124.125.400.315 D23.119.400.315
|
| Concept/Terms |
Factor Xa- Factor Xa
- Factor Ten A
- Activated Factor X
- Factor X, Activated
- Coagulation Factor Xa
- Factor Xa, Coagulation
- Blood Coagulation Factor X, Activated
- Thrombokinase
- Factor 10A
- Autoprothrombin C
|
Below are MeSH descriptors whose meaning is more general than "Factor Xa".
Below are MeSH descriptors whose meaning is more specific than "Factor Xa".
This graph shows the total number of publications written about "Factor Xa" by people in this website by year, and whether "Factor Xa" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2007 | 1 | 0 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2017 | 1 | 6 | 7 |
| 2018 | 5 | 7 | 12 |
| 2019 | 3 | 2 | 5 |
| 2020 | 2 | 1 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Factor Xa" by people in Profiles.
-
Effect of dexamethasone on direct Xa-inhibitor oral anticoagulant plasma levels in patients with COVID-19. Thromb Res. 2021 09; 205:106-109.
-
COVID-19-related laboratory coagulation findings. Int J Lab Hematol. 2021 Jul; 43 Suppl 1:36-42.
-
Potential Therapeutic Roles for Direct Factor Xa Inhibitors in Coronavirus Infections. Am J Cardiovasc Drugs. 2020 Dec; 20(6):525-533.
-
Discordance in activated partial thromboplastin time and anti-factor Xa levels in COVID-19 patients on heparin therapy. Thromb Res. 2021 02; 198:79-82.
-
Anti-Xa monitoring improves low-molecular-weight heparin effectiveness in patients with SARS-CoV-2 infection. Thromb Res. 2020 12; 196:432-434.
-
Filter clotting with continuous renal replacement therapy in COVID-19. J Thromb Thrombolysis. 2021 May; 51(4):966-970.
-
Impact of implementation of an individualised thromboprophylaxis protocol in critically ill ICU patients with COVID-19: A longitudinal controlled before-after study. Thromb Res. 2020 10; 194:209-215.
-
Thromboembolic events and apparent heparin resistance in patients infected with SARS-CoV-2. Int J Lab Hematol. 2020 06; 42 Suppl 1:19-20.
-
In Silico Evaluation of the Effectivity of Approved Protease Inhibitors against the Main Protease of the Novel SARS-CoV-2 Virus. Molecules. 2020 May 29; 25(11).
-
The old but new: Can unfractioned heparin and low molecular weight heparins inhibit proteolytic activation and cellular internalization of SARS-CoV2 by inhibition of host cell proteases? Med Hypotheses. 2020 Sep; 142:109743.